Source: https://brinksgilson.com/biographies/yuezhong-feng
Timestamp: 2019-04-25 14:24:35+00:00

Document:
With a Ph.D. in organic chemistry, Yuezhong Feng is used to handling challenging subject matter. He puts his technical knowledge to work litigating complex patent, Hatch-Waxman (ANDA), trade secret, International Trade Commission Section 337, and USPTO post-grant (inter partes review) cases, as well as guiding clients through the patent process. He also counsels clients on all aspects of U.S. intellectual property laws.
As co-chair of the firm’s China task force, Yuezhong often works with Chinese businesses entering the U.S. market. He excels at helping these clients bridge the gap between Chinese business and legal cultures and those found in the United States. As a result, companies in diverse industries rely on him to help maximize profit and reduce risk at every step of the patent process, from identifying patentable inventions to developing prosecution strategies, to portfolio management and monetization, to enforcement. Due to his deep understanding of Chinese markets, Yuezhong frequently assists U.S. and European companies with intellectual property issues in China.
Yuezhong has helped companies seek patent protection in more than 100 countries. In preparing patent applications, he thinks forward toward how to achieve consistent protection in global markets worldwide.
Yuezhong has particular experience in the chemical, pharmaceuticals, biotechnology, nanotechnology, electrical vehicles, chemical engineering (particularly bio-fuels and bio-diesels), mechanical (particularly home appliances and e-cigarettes), and electrical engineering (particularly telecommunication and liquid-crystal display devices) arts.
Pfizer v. Sandoz Inc. (D.N.J.). Litigated patents under Hatch Waxman (ANDA) related to pregabalin sold by Pfizer as Lyrica®, working on all aspects of the case including discovery, expert testimony, briefing, witness preparation and depositions.
Avanir Pharmaceuticals, Inc. et al. v. Watson Pharmaceuticals, Inc. (D. Del.). Represented Watson in patent litigation under Hatch Waxman (ANDA) related to dextromethorphan hydrobromide quinidine sulfate sold by Avanir as Nuedexta®.
Teijin Ltd., Teijin Pharma Ltd., and Takeda Pharma. U.S.A., Inc. v. Alembic Pharma. Ltd., (D. Del.). Representing Alembic in patent litigation under Hatch Waxman (ANDA) related to febuxostat sold by Takeda as Uloric®.
InterDigital Communications, Inc. et al. v. ZTE Corp., and ZTE (USA) Inc., (D. Del.); Technology Properties Limited, LLC et al. v. ZTE Corp., and ZTE (USA) Inc. (N. D. Cal.); InterDigital Comm., LLC, InterDigital Tech. Corp., And IPR Licensing, Inc. v. Huawei Tech. Co., Ltd., Futurewei Tech., Inc. d/b/a Huawei Tech. (USA) America, Nokia Corp., Nokia Inc., ZTE Corp., And ZTE (USA) Inc., (D. Del.); Certain Wireless Consumer Electronics Devices and Components Thereof (ITC); Certain Wireless Devices With 3G And/Or 4G Capabilities And Components Thereof (ITC.) Successfully represented ZTE Corporation and ZTE (USA) Inc. in actions at the International Trade Commission and U.S. federal district court, preserving ZTE’s ability to do business in the United States.
Blue Spike, LLC v. Oppo Digital, Inc., Guangdong Oppo Electronics Industry Co., (E.D. Tex.). Defended Guangdong Oppo Electronics Industry Co., Ltd. in district court action against a non-practicing entity (NPE). Plaintiff withdrew all claims at an early stage of litigation.
Long Corner Consumer Electronics LLC v. Coolpad Technologies Inc., (E. D. Tex.). Achieved an early settlement in for Coolpad Technologies in a district court action against an NPE.
"The Synergy Peptide PHSRN and the Adhesion Peptide RGD Mediate Cell Adhesion through a Common Mechanism," Co-author, 43, 15811-15821.
Direct Cell Adhesion to the Angiopoietins Mediated by Integrins." Co-author, 276, 26516-26525.
American Patents LLC v. Hisense Co. Ltd. et al, No. 4:18-cv-00768 (E.D. Tex. filed October 26, 2018). Representing Hisense in the district court patent action.
American Patents LLC v. ZTE Corporation et al, No. 4:18-cv-00675 (E.D. Tex. filed September 24, 2018). Representing ZTE in the district court patent action.
AstraZeneca LP et al. v. Hisun Pharmaceutical (Hangzhou) Co., Ltd. et al., C. A. No. 1:18-cv-1232 (D. Del filed August 10, 2018). Representing Hisun in patent litigation under Hatch Waxman (ANDA) related to ticagrelor sold by AstraZeneca as Brilinta®.
R.J. Reynolds Vapor Company v. Fontem Holdings 1 B.V., Nos. 2018-1591, -1598 (Fed. Cir. 2018-present). Representing R.J. Reynolds Vapor Co. in appealing decisions of the Patent Trial and Appeal Board.
Fontem Ventures B.V. and Fontem Holdings 1 B.V. v. R.J. Reynolds Vapor Co. (C.D. Cal. 2016-present; transferred to M.D.N.C.). Representing R.J. Reynolds Vapor Co. in the district court patent actions.
Codec Technologies LLC v. Coolpad Technologies Inc., C.A. No. 2:16-cv-00307 (E.D. Tex filed March 30, 2016). Represented Coolpad Technologies Inc. in the district court patent action.
AstraZeneca LP et al. v. Hisun Pharmaceutical (Hangzhou) Co., Ltd. et al., C. A. No. 1:15-cv-1042 (D. Del. filed November 12, 2015). Representing Hisun in patent litigation under Hatch Waxman (ANDA) related to ticagrelor sold by AstraZeneca as Brilinta®.
Noven Therapeutics, LLC. v. Actavis Laboratories FL, Inc., et al., C. A. Nos. 2:14-cv-6414 (D.N.J. filed October 16, 2014) and 2:15-cv-06225 (D.N.J. filed August 14, 2015)(consolidated). Representing Actavis in patent litigation under Hatch Waxman (ANDA) related to paroxetine mesylate sold by Noven as Brisdelle®.
Long Corner Consumer Electronics LLC v. Coolpad Technologies Inc., C. A. No. 2:13-cv-1004 (E. D. Tex. filed November 26, 2013). Represented Coolpad Technologies Inc. in the district court patent action.
Teijin Ltd., Teijin Pharma Ltd., and Takeda Pharma. U.S.A., Inc. v. Alembic Pharma. Ltd., C. A. No. 13-01939-SLR (D. Del. filed November 19, 2013). Represented Alembic in patent litigation under Hatch Waxman (ANDA) related to febuxostat sold by Takeda as Uloric®.
Blue Spike, LLC v. Oppo Digital, Inc., Guangdong Oppo Electronics Industry Co., Ltd., C. A. No. 13-752 (E.D. Tex. filed October 8, 2013). Represented Guangdong Oppo Electronics Industry Co., Ltd. in the district court patent action.
Certain Wireless Devices With 3G And/Or 4G Capabilities And Components Thereof, ITC Inv. No. 337-TA-868. Represented respondents ZTE Corporation and ZTE (USA) Inc. in the ITC investigation.
InterDigital Communications, Inc. et al. v. ZTE Corp., and ZTE (USA) Inc., C. A. No. 13-00009-RGA (D. Del. filed January 2, 2013). Represented defendants ZTE Corporation and ZTE (USA) Inc. in the district court patent action.
Certain Wireless Consumer Electronics Devices and Components Thereof, ITC Inv. No. 337-TA-853. Represented respondents ZTE Corporation and ZTE (USA) Inc. in the ITC investigation.
Technology Properties Limited, LLC et al. v. ZTE Corp., and ZTE (USA) Inc., C. A. No. 12-03876-PSG (N. D. Cal. filed July 24, 2012). Represented defendants ZTE Corporation and ZTE (USA) Inc. in the district court patent action.
Avanir Pharmaceuticals, Inc. et al. v. Watson Pharmaceuticals, Inc. et al., C. A. No. 12-cv-258 (D. Del. filed March 2, 2012). Represented Watson in patent litigation under Hatch Waxman (ANDA) related to dextromethorphan hydrobromide quinidine sulfate sold by Avanir as Nuedexta®.
Certain Wireless Devices With 3G Capabilities And Components Thereof, ITC No. 337-TA-800. Represented respondents ZTE Corporation and ZTE (USA) Inc. in the ITC investigation.
InterDigital Comm., LLC, InterDigital Tech. Corp., And IPR Licensing, Inc. v. Huawei Tech. Co., Ltd., Futurewei Tech., Inc. d/b/a Huawei Tech. (USA) America, Nokia Corp., Nokia Inc., ZTE Corp., And ZTE (USA) Inc., C. A. No. 11-654-MSG (D. Del. filed July 28, 2011). Represented defendants ZTE Corporation and ZTE (USA) Inc. in the district court patent action.
Certain Electric Fireplaces, Components Thereof, Manuals For Same, Certain Processes For Manufacturing Or Relating To Same, And Certain Products Containing Same, ITC No. 337-TA-791. Represented complainants Twin-Star International, Inc. and TS Investment Holding Corp. in the ITC investigation.
Pfizer v. Sandoz Inc., C. A. No. 09-cv-2052 (D.N.J. filed April 30, 2009). Litigated patents under Hatch Waxman (ANDA) related to pregabalin sold by Pfizer as Lyrica®.
ZTE (USA), Inc. v. Cywee Group, Ltd. (IPR2019-00526). Subject: U.S. Patent 8,441,438. Mr. Feng is counsel for Petitioner ZTE.
ZTE (USA), Inc. v. Cywee Group, Ltd. (IPR2019-00525). Subject: U.S. Patent 8,552,978. Mr. Feng is counsel for Petitioner ZTE.
ZTE (USA), Inc. v. Seven Networks, LLC (IPR2019-00585). Subject: U.S. Patent 9,247,019. Mr. Feng is counsel for Petitioner ZTE.
ZTE (USA), Inc. v. Seven Networks, LLC (IPR2019-00461). Subject: U.S. Patent 9,516,129. Mr. Feng is counsel for Petitioner ZTE.
ZTE (USA), Inc. v. Seven Networks, LLC (IPR2019-00460). Subject: U.S. Patent 9,516,127. Mr. Feng is counsel for Petitioner ZTE.
ZTE (USA), Inc. v. Seven Networks, LLC (IPR2019-00412). Subject: U.S. Patent 9,351,254. Mr. Feng is counsel for Petitioner ZTE.
R.J. Reynolds Vapor Company v. Fontem Holdings 1B.V. (IPR2018-00634). Subject: U.S. Patent 9,456,632. Mr. Feng is counsel for Petitioner R.J. Reynolds Vapor Company.
R.J. Reynolds Vapor Company v. Fontem Holdings 1B.V. (IPR2018-00627). Subject: U.S. Patent 8,393,331. Mr. Feng is counsel for Petitioner R.J. Reynolds Vapor Company.
R.J. Reynolds Vapor Company v. Fontem Holdings 1B.V. (IPR2017-01642). Subject: U.S. Patent 9,370,205. Mr. Feng is counsel for Petitioner R.J. Reynolds Vapor Company.
R.J. Reynolds Vapor Company v. Fontem Holdings 1B.V. (IPR2017-01641). Subject: U.S. Patent 9,370,205. Mr. Feng is counsel for Petitioner R.J. Reynolds Vapor Company.
R.J. Reynolds Vapor Company v. Fontem Holdings 1 B.V. (IPR2016-01692). Subject U.S. Patent 9,326,548. Mr. Feng is counsel for Petitioner R.J. Reynolds Vapor Company.
R.J. Reynolds Vapor Company v. Fontem Holdings 1 B.V. (IPR2016-01691). Subject: U.S. Patent 9,326,548. Mr. Feng is counsel for Petitioner R.J. Reynolds Vapor Company.
R.J. Reynolds Vapor Company v. Fontem Holdings 1 B.V. (IPR2016-01532). Subject: U.S. Patent 8,365,742. Mr. Feng is counsel for Petitioner R.J. Reynolds Vapor Company.
R.J. Reynolds Vapor Company v. Fontem Holdings 1 B.V. (IPR2016-01272). Subject: U.S. Patent 8,899,239. Mr. Feng is counsel for Petitioner R.J. Reynolds Vapor Company.
R.J. Reynolds Vapor Company v. Fontem Holdings 1 B.V. (IPR2016-01268). Subject: U.S. Patent 8,365,742. Mr. Feng is counsel for Petitioner R.J. Reynolds Vapor Company.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.